Rituximab reduces anti-cardiolipin levels in patients with systemic lupus erythematosus
- PDF / 161,931 Bytes
- 1 Pages / 595.276 x 793.701 pts Page_size
- 92 Downloads / 208 Views
POSTER PRESENTATION
Open Access
Rituximab reduces anti-cardiolipin levels in patients with systemic lupus erythematosus R Martínez-Pérez1*, A Muñoz-Jiménez1, S Rodríguez-Montero1, A Fernández-Nebro2, L Carreño3, J L Marenco1 From 5th European Workshop on Immune-Mediated Inflammatory Diseases Sitges-Barcelona, Spain. 1-3 December 2010 Introduction Patients with systemic lupus erythematosus (SLE), can produce antibodies directed against the complex phospholipds-b-glycoprotein 1. Rituximab is an antibody directed to most B-cells, except precursors and mature plasma cells. It can produce reductions in antibody titers. We have treated SLE patients refractory to conventional immunosuppressive therapy, with Rituximab and we searched for a reduction in anticardiolipin autoantibodies. Material and methods We have performed an observational, retrospective and multicentric study from 3 Spanish hospitals. We analysed 46 patients with complex clinical index (SLEDAI, physician global assessment scale) and laboratory determinations, included anticardiolipin levels, at start, week 24 and final visit. Results We have treated 46 patients, 3 men and 43 women, 91.3% Caucasians. Antiphospholipid syndrome was present in 14 patients (30.4%). A Lupus Anticoagulant (LA) was detected in 42.9%. 40 patients received the dose for arthritis (2x1g) and 4x375mg/m2 in the others. The mean of cycles used was 2 (1-3). After the Rituximab therapy the LA was positive in only 10% (p
Data Loading...
